Cite
Bentzen BH, Bomholtz SH, Simó-Vicens R, et al. Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man. Front Pharmacol. 2020;11:610doi: 10.3389/fphar.2020.00610.
Bentzen, B. H., Bomholtz, S. H., Simó-Vicens, R., Folkersen, L., Abildgaard, L., Speerschneider, T., Muthukumarasamy, K. M., Edvardsson, N., Sørensen, U. S., Grunnet, M., & Diness, J. G. (2020). Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man. Frontiers in pharmacology, 11610. https://doi.org/10.3389/fphar.2020.00610
Bentzen, Bo Hjorth, et al. "Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man." Frontiers in pharmacology vol. 11 (2020): 610. doi: https://doi.org/10.3389/fphar.2020.00610
Bentzen BH, Bomholtz SH, Simó-Vicens R, Folkersen L, Abildgaard L, Speerschneider T, Muthukumarasamy KM, Edvardsson N, Sørensen US, Grunnet M, Diness JG. Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man. Front Pharmacol. 2020 May 06;11:610. doi: 10.3389/fphar.2020.00610. eCollection 2020. PMID: 32477117; PMCID: PMC7232560.
Copy
Download .nbib